BioWorld

Nov. 15, 2005

Viventia Merging, Becoming Private: C$12M To Pay Debt

PDUFA Being Reviewed Prior To Reauthorization

Speedel Presents Confirmatory Positive SPP301 Phase II Data

Other News To Note

OSI, Eyetech Close Merger After Look At Lucentis Data

Although it had to work on the weekend to calm any fears, OSI Pharmaceuticals Inc. closed its merger with Eyetech Pharmaceuticals Inc. Monday - much to the chagrin of some OSI analysts and investors. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...